Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors

•We explored relapse-free survival (RFS) as a surrogate for overall survival (OS).•We used data from the European Organisation for Research and Treatment of Cancer 18071 trial and published results from other trials.•We found a strong association between RFS and OS at the patient level.•We found a moderate association between RFS and OS at the trial level.•Our results are promising and require confirmation with a larger number of trials.